Puma Ptb Ratio vs Book Value Per Share Analysis

PBYI Stock

USD 3.21 0.13 4.22%

Puma Biotechnology financial indicator trend analysis is much more than just breaking down Puma Biotechnology prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Puma Biotechnology is a good investment. Please check the relationship between Puma Biotechnology Ptb Ratio and its Book Value Per Share accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Puma Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.

Ptb Ratio vs Book Value Per Share

Ptb Ratio vs Book Value Per Share Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Puma Biotechnology Ptb Ratio account and Book Value Per Share. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Puma Biotechnology's Ptb Ratio and Book Value Per Share is -0.16. Overlapping area represents the amount of variation of Ptb Ratio that can explain the historical movement of Book Value Per Share in the same time period over historical financial statements of Puma Biotechnology, assuming nothing else is changed. The correlation between historical values of Puma Biotechnology's Ptb Ratio and Book Value Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ptb Ratio of Puma Biotechnology are associated (or correlated) with its Book Value Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Book Value Per Share has no effect on the direction of Ptb Ratio i.e., Puma Biotechnology's Ptb Ratio and Book Value Per Share go up and down completely randomly.

Correlation Coefficient

-0.16

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Ptb Ratio

Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.

Book Value Per Share

The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.

Most indicators from Puma Biotechnology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Puma Biotechnology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Puma Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.As of now, Puma Biotechnology's Enterprise Value Over EBITDA is increasing as compared to previous years. The Puma Biotechnology's current Enterprise Value Multiple is estimated to increase to 3.35, while Selling General Administrative is projected to decrease to under 67 M.

	2022	2023	2024	2025 (projected)
Reconciled Depreciation	8.9M	10.2M	11.5M	9.6M
Interest Income	813K	2.4M	4.7M	5.0M

Reconciled Depreciation Interest Income

Puma Biotechnology fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Net Debt	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Total Current Liabilities	Retained Earnings	Accounts Payable	Other Current Liab	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Retained Earnings Total Equity	Short Term Investments	Non Current Liabilities Total	Capital Surpluse	Inventory
Total Assets		0.17	0.19	0.51	0.47	-0.64	0.45	0.84	0.69	0.89	-0.64	0.74	-0.76	0.55	0.66	0.51	-0.12	0.55	0.64	0.47	0.4	-0.76	0.31	0.6	0.82	-0.02
Total Stockholder Equity	0.17		-0.77	0.38	0.4	-0.28	-0.4	-0.25	-0.59	0.56	-0.28	-0.41	0.36	0.21	-0.55	-0.4	0.92	-0.52	-0.57	0.41	0.53	0.36	0.58	-0.64	-0.24	0.14
Net Debt	0.19	-0.77		-0.56	-0.56	0.06	0.61	0.49	0.72	-0.17	0.06	0.62	-0.58	0.01	0.65	0.43	-0.8	0.58	0.7	0.0	-0.24	-0.58	-0.02	0.7	0.5	-0.01
Cash	0.51	0.38	-0.56		0.96	-0.43	-0.08	0.31	0.14	0.59	-0.43	0.14	-0.24	0.25	0.14	0.17	0.22	0.06	0.08	-0.03	0.11	-0.24	-0.25	0.12	0.29	-0.22
Cash And Short Term Investments	0.47	0.4	-0.56	0.96		-0.47	-0.03	0.3	0.09	0.56	-0.47	0.15	-0.23	0.2	0.1	0.18	0.22	0.01	0.07	-0.06	0.04	-0.22	-0.26	0.05	0.29	-0.25
Common Stock Total Equity	-0.64	-0.28	0.06	-0.43	-0.47		0.12	-0.43	-0.32	-0.63	1.0	-0.4	0.39	-0.36	-0.33	-0.22	0.02	-0.25	-0.32	-0.38	-0.25	0.39	-0.2	-0.23	-0.41	-0.1
Common Stock Shares Outstanding	0.45	-0.4	0.61	-0.08	-0.03	0.12		0.78	0.66	0.13	0.12	0.74	-0.77	0.13	0.61	0.58	-0.5	0.49	0.76	0.01	-0.19	-0.76	-0.13	0.55	0.81	-0.1
Other Stockholder Equity	0.84	-0.25	0.49	0.31	0.3	-0.43	0.78		0.87	0.53	-0.43	0.92	-0.97	0.44	0.83	0.67	-0.51	0.7	0.91	0.19	0.04	-0.96	-0.05	0.76	0.99	-0.16
Total Liab	0.69	-0.59	0.72	0.14	0.09	-0.32	0.66	0.87		0.32	-0.32	0.91	-0.89	0.3	0.95	0.71	-0.77	0.83	0.94	0.09	-0.07	-0.89	-0.17	0.96	0.85	-0.12
Total Current Assets	0.89	0.56	-0.17	0.59	0.56	-0.63	0.13	0.53	0.32		-0.63	0.38	-0.43	0.56	0.29	0.18	0.3	0.22	0.23	0.58	0.6	-0.42	0.54	0.26	0.51	0.06
Common Stock	-0.64	-0.28	0.06	-0.43	-0.47	1.0	0.12	-0.43	-0.32	-0.63		-0.4	0.39	-0.36	-0.33	-0.22	0.02	-0.25	-0.32	-0.38	-0.25	0.39	-0.2	-0.23	-0.41	-0.1
Total Current Liabilities	0.74	-0.41	0.62	0.14	0.15	-0.4	0.74	0.92	0.91	0.38	-0.4		-0.92	0.26	0.92	0.77	-0.67	0.8	0.95	0.14	-0.1	-0.91	-0.11	0.76	0.92	0.0
Retained Earnings	-0.76	0.36	-0.58	-0.24	-0.23	0.39	-0.77	-0.97	-0.89	-0.43	0.39	-0.92		-0.34	-0.86	-0.68	0.61	-0.73	-0.94	-0.12	0.09	1.0	0.13	-0.76	-0.97	0.17
Accounts Payable	0.55	0.21	0.01	0.25	0.2	-0.36	0.13	0.44	0.3	0.56	-0.36	0.26	-0.34		0.16	0.04	0.03	0.2	0.22	0.73	0.74	-0.35	0.4	0.32	0.39	0.11
Other Current Liab	0.66	-0.55	0.65	0.14	0.1	-0.33	0.61	0.83	0.95	0.29	-0.33	0.92	-0.86	0.16		0.71	-0.74	0.89	0.94	0.02	-0.14	-0.87	-0.22	0.86	0.81	-0.14
Other Liab	0.51	-0.4	0.43	0.17	0.18	-0.22	0.58	0.67	0.71	0.18	-0.22	0.77	-0.68	0.04	0.71		-0.58	0.68	0.79	-0.06	-0.19	-0.68	-0.26	0.6	0.68	-0.14
Net Tangible Assets	-0.12	0.92	-0.8	0.22	0.22	0.02	-0.5	-0.51	-0.77	0.3	0.02	-0.67	0.61	0.03	-0.74	-0.58		-0.65	-0.77	0.3	0.48	0.61	0.51	-0.75	-0.51	0.15
Property Plant And Equipment Net	0.55	-0.52	0.58	0.06	0.01	-0.25	0.49	0.7	0.83	0.22	-0.25	0.8	-0.73	0.2	0.89	0.68	-0.65		0.81	0.08	-0.05	-0.74	-0.17	0.76	0.68	-0.14
Non Current Assets Total	0.64	-0.57	0.7	0.08	0.07	-0.32	0.76	0.91	0.94	0.23	-0.32	0.95	-0.94	0.22	0.94	0.79	-0.77	0.81		0.03	-0.18	-0.94	-0.24	0.84	0.9	-0.14
Non Currrent Assets Other	0.47	0.41	0.0	-0.03	-0.06	-0.38	0.01	0.19	0.09	0.58	-0.38	0.14	-0.12	0.73	0.02	-0.06	0.3	0.08	0.03		0.86	-0.13	0.75	0.06	0.15	0.56
Other Assets	0.4	0.53	-0.24	0.11	0.04	-0.25	-0.19	0.04	-0.07	0.6	-0.25	-0.1	0.09	0.74	-0.14	-0.19	0.48	-0.05	-0.18	0.86		0.09	0.74	-0.01	-0.01	0.32
Retained Earnings Total Equity	-0.76	0.36	-0.58	-0.24	-0.22	0.39	-0.76	-0.96	-0.89	-0.42	0.39	-0.91	1.0	-0.35	-0.87	-0.68	0.61	-0.74	-0.94	-0.13	0.09		0.13	-0.77	-0.97	0.17
Short Term Investments	0.31	0.58	-0.02	-0.25	-0.26	-0.2	-0.13	-0.05	-0.17	0.54	-0.2	-0.11	0.13	0.4	-0.22	-0.26	0.51	-0.17	-0.24	0.75	0.74	0.13		-0.19	-0.06	0.34
Non Current Liabilities Total	0.6	-0.64	0.7	0.12	0.05	-0.23	0.55	0.76	0.96	0.26	-0.23	0.76	-0.76	0.32	0.86	0.6	-0.75	0.76	0.84	0.06	-0.01	-0.77	-0.19		0.72	-0.18
Capital Surpluse	0.82	-0.24	0.5	0.29	0.29	-0.41	0.81	0.99	0.85	0.51	-0.41	0.92	-0.97	0.39	0.81	0.68	-0.51	0.68	0.9	0.15	-0.01	-0.97	-0.06	0.72		-0.16
Inventory	-0.02	0.14	-0.01	-0.22	-0.25	-0.1	-0.1	-0.16	-0.12	0.06	-0.1	0.0	0.17	0.11	-0.14	-0.14	0.15	-0.14	-0.14	0.56	0.32	0.17	0.34	-0.18	-0.16

Click cells to compare fundamentals

Puma Biotechnology Account Relationship Matchups

Puma Biotechnology fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	244.2M	226.6M	222.1M	230.5M	213.3M	168.9M
Total Stockholder Equity	(6M)	(2.4M)	21.6M	53.4M	92.1M	65.1M
Net Debt	35.7M	53.5M	38.1M	26.9M	4.9M	5.1M
Cash	85.3M	63.1M	76.2M	84.6M	69.2M	69.0M
Cash And Short Term Investments	85.3M	63.1M	76.2M	95.9M	101.0M	74.1M
Common Stock Shares Outstanding	39.6M	40.6M	44.9M	47.6M	49.1M	33.9M
Liabilities And Stockholders Equity	244.2M	226.6M	222.1M	230.5M	213.3M	168.9M
Other Stockholder Equity	1.3B	1.4B	1.4B	1.4B	1.4B	806.5M
Total Liab	250.2M	229.0M	200.5M	177.1M	121.2M	110.0M
Total Current Assets	146.1M	140.0M	134.3M	156.2M	147.7M	128.9M
Total Current Liabilities	114.3M	109.6M	77.5M	99.4M	96.1M	59.7M
Retained Earnings	(1.3B)	(1.4B)	(1.4B)	(1.3B)	(1.3B)	(1.2B)
Accounts Payable	12.1M	11.2M	6.4M	6.9M	5.5M	5.2M
Other Current Liab	81.7M	91.3M	66.9M	53.7M	39.7M	43.4M
Other Liab	9M	32.3M	6.4M	12.8M	14.7M	7.6M
Net Tangible Assets	(23.0M)	(80.1M)	(68.6M)	21.6M	19.4M	18.5M
Property Plant And Equipment Net	18.9M	15.8M	12.5M	8.6M	5.1M	8.2M
Non Current Assets Total	98.1M	86.6M	87.8M	74.3M	65.7M	51.4M
Non Currrent Assets Other	5.1M	4.7M	4.7M	4.8M	2.4M	4.4M
Other Assets	5.1M	4.7M	4.7M	1.0	0.9	0.86
Long Term Debt	84.0M	97.1M	98.3M	65.7M	21.7M	20.6M
Retained Earnings Total Equity	(1.3B)	(1.3B)	(1.4B)	(1.4B)	(1.2B)	(1.3B)
Short Term Investments	8.1M	19.0M	4.9M	11.4M	31.7M	31.2M
Non Current Liabilities Total	135.9M	119.4M	123.0M	77.7M	25.1M	23.8M
Capital Surpluse	1.3B	1.3B	1.4B	1.4B	1.6B	952.6M
Inventory	3.5M	7.1M	4.5M	7.1M	8.7M	8.1M
Other Current Assets	23.8M	18.3M	8.3M	4.7M	6.0M	9.6M
Deferred Long Term Liab	5.8M	868K	955K	743K	854.5K	811.7K
Property Plant And Equipment Gross	18.9M	22.6M	1.1M	16.3M	13.0M	9.1M
Accumulated Other Comprehensive Income	62K	0.0	(2K)	(4K)	6K	6.3K
Intangible Assets	74.1M	66.1M	70.6M	60.9M	51.1M	35.8M
Property Plant Equipment	3.3M	2.5M	15.8M	1.1M	1.3M	1.3M
Net Receivables	25.5M	32.5M	40.4M	48.5M	32.0M	26.2M
Short Long Term Debt Total	121.0M	116.6M	114.3M	111.5M	74.1M	85.8M
Long Term Debt Total	151.9M	95.0M	84.0M	97.1M	111.7M	104.8M
Net Invested Capital	92.4M	94.6M	119.9M	153.1M	159.2M	140.2M
Net Working Capital	31.9M	30.4M	56.8M	56.8M	51.5M	48.7M

Currently Active Assets on Macroaxis

AMT	American Tower Corp
HLTOY	Hellenic Telecommunications Org
NFLX	Netflix
EPGFX	Europac Gold Fund
FTGFF	Firan Technology Group

When determining whether Puma Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Puma Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Puma Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Puma Biotechnology Stock:

How To Invest In Puma

Details

Is Puma Stock a good investment?

Details

What is Puma Biotechnology's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Puma Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.

You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Puma Biotechnology. If investors know Puma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.585

Earnings Share

0.62

Revenue Per Share

4.737

Quarterly Revenue Growth

(0.18)

Return On Assets

0.0872

The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Puma Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Puma Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Puma Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Puma Ptb Ratio vs Book Value Per Share Analysis

Ptb Ratio vs Book Value Per Share

Ptb Ratio vs Book Value Per Share Correlation Analysis

Correlation Coefficient

Ptb Ratio

Book Value Per Share

Puma Biotechnology fundamental ratios Correlations

Puma Biotechnology Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Puma Biotechnology fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Common Stock Total Equity
Retained Earnings Total Equity	+ 1.0	Retained Earnings
Capital Surpluse	+ 0.99	Other Stockholder Equity
Cash And Short Term Investments	+ 0.96	Cash
Non Current Liabilities Total	+ 0.96	Total Liab
Other Current Liab	+ 0.95	Total Liab

Capital Surpluse	- 0.97	Retained Earnings Total Equity
Capital Surpluse	- 0.97	Retained Earnings
Retained Earnings	- 0.97	Other Stockholder Equity
Retained Earnings Total Equity	- 0.96	Other Stockholder Equity
Retained Earnings Total Equity	- 0.94	Non Current Assets Total
Non Current Assets Total	- 0.94	Retained Earnings